



Multi-organ failure and antifungal treatment
R. J. M. Bru¨ggemann1 and R. Lewis2
1Radboud University Medical Center, Nijmegen, the Netherlands
and 2University of Bologna, Bologna, Italy
Critically ill patients with life threatening infections often experience
multi-organ failure. These patients who are frequently hemodynamic
unstable, require aggressive therapeutic interventions that will
impact the pharmacokinetics of antifungal drugs. Vice versa, antifun-
gal drugs are not without side-effects likely causing a further deterio-
ration of specific organ functions. Applying effective (and safe) drug
regimens for these patients with the selection of the most appropriate
drug and to optimize the exposure of these drug, requires under-
standing of the pharmacokinetics.
In the treatment of fungal infections in hematology and ICU
patients, the heterogeneous nature of patients combined with limited
evidence on how to manage these patients often leads to a high vari-
ability of applied drug regimens and regular off-label drug use. Fail-
ure to anticipate and monitor for changes in the pharmacokinetics of
a drug can contribute to clinical failures or adverse drug events.
In this session we will discuss the general principles of PK of anti-
fungal drugs and how critical illness can influence the specific phar-
macokinetic phases (absorption, distribution, metabolism and
elimination).
We will start with current challenges in oral absorption of antifun-
gal drugs, the differences in oral bioavailability and the impact of
food-drug interactions. Next we will discuss if we can identify certain
drug that might have a preferential profile for targeting certain organ
systems (distribution) and the impact of a wide variety of factors that
influence distribution of antifungal drugs such as protein binding.
With drug metabolism, we discuss the impact of hepatic enzyme
activity on the pharmacokinetics. Finally, we review drug elimination
and discuss the impact of renal function (kidney injury) and topics
such as augmented renal clearance. The role of extracorporeal elimi-
nation techniques such as CVVH(D)(F) and ECMO on the pharma-
cokinetics of antifungal drugs will be touched upon.
For the purpose of this section, we will highlight relevant literature
and characterize the impact of above mentioned factors on the PK
profile and, where appropriate, provide general suggestions on how
to adapt drug regimens to manage specific challenges. Finally recom-
mendations will be made on the role of therapeutic drug monitoring
to guide dosing in the setting of critical illness.
In short, the following will be addressed: (i) potential impact of
critical illness on the pharmacokinetic (implications for absorption,
distribution, metabolism and elimination; including hepatic and renal
dysfunction, extracorporeal elimination techniques etc; (ii) choice of
drug in the setting of critical illness and specific organ dysfunction
(including safety related aspects); and (iii) the role of TDM for dosage
adjustment to achieve optimal drug exposure for individual patients
in the setting of organ dysfunction.
M02
Professional exposure to fungal pathogens - an update to
exposure conditions and exposure measurement
S. Mayer1 and C. Viegas2
1Berufsgenossenschaft Handel und Warenlogistik, Mannheim,
Germany and 2Environment & Health RG - Lisbon School of
Health Technology - Polytechnic Insti, Lisbon, Portugal
In many occupational settings an exposure to fungi occurs. Fungal
exposure may occur for instance in the form of dermatocytes, yeasts
or mold. Associated to the fungi themselves an exposure to cell wall
components like ß(1 ? 3)-D-glucans, to mycotoxins or to microbial
volatile compounds can occur. Health hazards may differ across spe-
cies because fungi may produce different allergens and mycotoxins,
and some species can infect humans.
Occupational settings are often characterized by special exposure
conditions with respect to duration, frequency and especially to the
level of exposure resulting at least sometimes to high or very high
fungal exposure. Because of these special conditions occupational set-
tings are suitable for epidemiologic studies. However, the knowledge
about occupational exposure to fungi and associated compounds like
mycotoxins is still fragmentary and not well disseminated. An indica-
tion for a high fungal exposure is for instance the handling of dry
natural products like grain, hay or herbal plants with a high specific
surface and the tendency to release dust during handling. The fungal
components often form the determinative part of such dusts and
might be a vehicle to respiratory airways.
The authors will present results of exposure measurements of
occupational settings and exposure conditions which are only rarely
investigated.
For a sound risk assessment a profound exposure characterization
is indispensable. However, each measurement technique has limita-
tions. Thus it is necessary to be aware of which information can be
achieved by the different measurement techniques. Very common is
the use of cultivation based methods. But not for all fungi appropri-
ate culture media are available and slow growing fungi can be over-
grown. In the case of the search for distinct fungi the use methods
like the real-time quantitative PCR (qPCR) amplification of genes
from specific fungal species offers considerable advantages. Such
methods can also help for the comprehensive characterization of the
Table 1 Comparison between fungal assessment through conventional and
molecular methods.
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fungal diversity present at workplaces. For the latter objective the
investigation of settled dust is recommended as settled dust usually
acts like an integral of the airborne exposure over a longer period of
time than conventional methods with air sampler do.
A study about fungal exposure in Portuguese occupational settings
revealed that 64.2% of the sampling sites reveal different species in
surfaces than the ones identified in air. That corroborates the impor-
tance of surface analysis to complement the mycological air charac-
terization and it allows a more complete characterization regarding
fungal contamination. In addition, only A. fumigatus complex was
found through conventional methods and was not able to be detected
by molecular tools in cork industry among several occupational set-
tings previously assessed (Table 1).
M03
Fungal endocarditis
A. Lefort1 and P. Nun˜oz2
1Ho^pital Beaujon, Clichy, France and 2Hospital General
Universitario Gregorio Maran˜on, Madrid, Spain
Candida endocarditis is a very rare (<2% of all infective endocartitis
cases) but devastating disease. Recent hospital mortality rates are still
as high as 30–47%. Among Candida endocarditis, those affecting
prosthetic valves are even more severe. Current ESCMID guidelines
recommend antifungal treatment associated with early surgery for
prosthetic valve endocarditis due to Candida (PVE-C). If surgery is not
possible, life-long fluconazole may be prescribed, to suppress infec-
tion. These recommendations are based on the results of retrospective
reviews of case series, case reports or small prospective series, and
expert opinions, since prospective randomized studies are not possible
in the field of this rare disease affecting very heterogenous
populations.
The choice of the antifungal treatment may take into account the
fungicidal properties of the molecules, and their activity against Can-
dida biofilms. Liposomal amphotericin B formulations and echinocan-
dins may thus confer an advantage, although no clinical data
demonstrated their superiority. Early surgery is recommended on the
basis of the high frequency of embolic complications associated with
Candida endocarditis and the poor diffusion of antifungals through
cardiac vegetations and around foreign bodies, but clinical data vali-
dating this recommendation are very scarce. In addition, patients are
often poor surgical candidates. Results of the ESCAPE study analys-
ing the long-term outcome of patients with PVE-C managed in Spain
and France between 2005 and 2013, suggest that a prolonged sup-
pressive antifungal therapy could improve the outcome of unoperated
patients with PVE-C without major side effects.
M04
New diagnostic tools for Pneumocystis jirovecii
A. Alanio1 and O. M. G. Matos2
1Ho^pital Saint Louis, Paris, France and 2Instituto de Higiene e
Medicina Tropical, Lisboa, Portugal
In both the European Economic Area and the USA, Pneumocystis jiro-
vecii pneumonia (PcP) is the most commonly diagnosed AIDS-indica-
tive disease. The rising numbers of immunocompromised HIV-
negative patients at risk of P. jirovecii infection (those receiving
immunosuppressive therapies for malignancies, allogeneic bone mar-
row or solid organ transplantations or autoimmune diseases) are an
emerging concern.
PcP is difficult to diagnose, in particular in HIV-negative patients
owing to the nonspecific symptoms and signs associated. Since
P. jirovecii is not cultivable, microscopic visualization of cysts or
trophic forms in respiratory specimens based on cytochemical stain-
ings or immunofluorescence stainings using monoclonal antibodies
(IF/Mab) are the standard procedures to detect this fungus. Respira-
tory specimens obtained by invasive techniques (e.g. BAL) carry the
risk of complications and are not easy to collect in children and
patients with respiratory failure. Blood biomarkers could be a way to
perform PcP diagnosis non-invasively. Several studies performed
recently, explored the usefulness of candidate serum biomarkers,
such as (1-3)-b-D-Glucan (BG), Krebs von den Lungen-6 antigen (KL-
6), lactate dehydrogenase (LDH) or S-adenosyl Methionine (SAM),
with the former presenting the most promising results. BG detection
has a high sensitivity and a relatively high negative predictive value
for diagnosis of PcP in immunocompromised HIV-positive and -nega-
tive patients, but a positive result may also indicate the presence of
other invasive fungal infections.
In addition, PCR-based methods play an increasing role in the lab,
initially developed to circumvent decreased sensitivity of microscopy
in respiratory specimens and in HIV-negative patients. Real-time PCR
is the only format adapted to diagnosis since the risk of contamina-
tion is minimal and quantification is possible. Quantitative results
have been used for years to try to discriminate PcP (high fungal
load) from carriage/colonization (low fungal load). However, these
methodologies have limited use since intermediate fungal load are
inconclusive. Combination with BG detection in serum helps but do
not completely resolve the problem. With the ambition to bring a
new concept for diagnosing infectious diseases, a new diagnostic PCR
methodology based on the analysis of the expression of two genes
could revolutionize PcP diagnosis.
M05
Infection control & fungi: what’s hot and what’s flop?
J. P. Gangneux1 and B. Willinger2
1Rennes Teaching Hospital - Inserm U1085, Rennes, France and
2Medical University of Vienna, Division of Clinical Microbiology,
Vienna, Austria
Invasive Fungal Infections (IFI) caused by filamentous fungi such as
Aspergillus sp. are feared diseases despite the recent evolution of ther-
apeutic strategies. In order to avoid the exposure of the most at risk
patients such as those undergoing neutropenic chemotherapy, or
hematopoetic stem cell transplant recipients to fungal spores, air and
water contol measures are usually implemented in hospitals. Their
aim is to diminish the morbidity and mortality of these diseases,
thereby reducing the need for associated healthcare (extension of
hospital stay, prescription of complementary examinations and use of
antifungal medication). During the session, we will analysed succes-
sively the methods used for air and water treatment, in normal situa-
tions but also during construction works in healthcare
establishments, and how to monitor its efficacy.
M06
Meet the fungus - Rare fungal infections cases
J. Meis1 and B.-J. Kullberg2
1Canisius Wilhelmina Hospital, Nijmegen, the Netherlands and
2Radboud University Medical Centre, Nijmegen, the Netherlands
For the abstracts that will be discussed in this session, please see sec-
tion ‘poster sessions’, corresponding abstract numbers: P102/P200/
P122/P303.
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Genotyping fungal outbreaks and molecular epidemiology:
the state of the art
C. S. Pais1 and M. C. Fisher2
1University of Minho, Braga, Portugal and 2Imperial College
London, London, UK
The processes driving infectious disease emergence and spread are
reflected in their genetic diversity. Genotyping approaches are now
an integral part of research in infectious disease epidemiology.
Detailed individual- or species-level analyses of genetic diversity
informs our understanding of disease transmission and the evolution
and spread of antifungal resistance. Broader genomic analysis of
microbial communities within the host is revealing important inter-
actions between different fungal lineages, species and kingdoms, their
response to interventions and their role in shaping the immune
response to infection. This ‘meet the expert’ session will consider the
scientific potential for high-throughput genotyping data in fungal dis-
ease epidemiology and the new opportunities offered by advances in
genetic sequencing technology. We will consider the advantages and
disadvantages of currently used genotyping techniques, the types of
analyses that each platform supports, and the rapidly-developing
opportunities that are afforded by new genotyping technologies. Our
examples will be chosen to illustrate the spectrum of infectious fungi
that impact humans and other animals.
M08
Non-dermatophytes moulds in dermatology
D. M. L. Saunte1 and M. Schaller2
1Roskilde Hospital, Roskilde, Denmark and
2Universit€atshautklinik, T€ubingen, Germany
Non-dermatophytes are sometimes seen as pathogens in onychomy-
cosis and more rarely in skin infections.
The prevalence of non-dermatophytes (e.g. Neoscytalidium. Scopu-
lariopsis, Aspergillus and Fusarium) as etiological agents of onychomy-
cosis, varies in different studies depending on the definition of the
diagnostic criteria used. It is often necessary to resample in order to
confirm the diagnosis and exclude contamination. Secondary colo-
nization of nail changes e.g. after trauma or nail alteration caused
by diseases such as lichen planus or psoriasis is a challenge. The
choice of systemic or topical antifungal treatment or a combination
of antifungal treatment combined with chemical or mechanical nail
avulsion is chosen based on the extent of nail changes in conjunc-
tion with the patient’s other disorders and possible medication inter-
actions. New treatment options such as photodynamic therapy and
laser treatment are also available.
Skin infections caused by non-dermatophytes are rare in immune
competent patients but may occasionally be inoculated by trauma. In
immunosuppressive patients non-dermatophytes may disseminate by
haematological spread to the skin secondary to a systemic infection.
This session will focus on the clinical presentation as well as the
diagnostic and treatment challenges of non-dermatophytes in
dermatology.
M09
ECMM external quality control programmes
E. M. Johnson1 and P. E. Verweij2
1Public Health England, Bristol, UK and 2Radboudumc, Nijmegen,
the Netherlands
Participation in external quality assessment (EQA) plays a vital role
in the quality management and improvement of services offered by
clinical laboratories, thereby furthering the ultimate aim of ensuring
a high standard of patient care. At its best EQA provides laboratory
managers with an objective assessment of laboratory performance
against recognised standards and provides a bench mark relative to
peer performance in the same test. It can highlight issues with
methodology or kit performance and is a marker for the efficacy of
internal quality control (IQC). For commercially available kits it pro-
vides inter-laboratory performance evaluation and can be useful for
post-marketing vigilance. In some areas it can be educational, occa-
sionally challenging laboratories with results or organisms they may
only encounter infrequently, although the bedrock of good EQA is to
provide a test system for clinically relevant samples that mimic
patient samples that are processed on a daily basis. In order to fulfil
the remit EQA samples should be handled in the laboratory in
exactly the same way as routine clinical samples. Failure of the
intention of EQA occurs when samples are not handled in the same
way but are marked out for special attention e.g. greater care with
ensuring IQC is well in range, repeat testing of samples or calling
more experienced colleagues to assist with an identification if that
would not be normal laboratory practice for patient samples. This
may of course result in excellent performance in EQA but will not
help to highlight any issues thus helping to improve the overall per-
formance of that laboratory. Of course a more generalised discussion
or tutorial post result analysis and distribution is very beneficial for
laboratories and wide discussion and dissemination of EQA results
throughout the lab should be encouraged once the post analysis
report is received.
Increasingly, bodies that provide accreditation of clinical laboratory
performance are looking for participation in a range of EQA schemes
that encompass the entire repertoire of tests undertaken by a labora-
tory. Whilst the range of tests available for mycology services has
been expanding and now encompasses; identification and susceptibil-
ity testing of yeast and moulds, including dermatophytes; antibody
testing for candidosis and aspergillosis; antigen testing for cryptococ-
cosis; Aspergillus, Candida and Pneumocystis DNA detection; and a
wide range of antifungal assays, there are some notable gaps. We
will discuss the schemes that are available and discuss ways such as
inter-laboratory exchanges that can be used to fill the gaps until
standardised schemes are available for all the tests and services rou-
tinely conducted in mycology laboratories.
M10a
Are all potential human pathogenic Mucorales identical?
E. Dannaoui
Paris-Descartes University, Paris, France
Mucormycosis is an emerging infection due to several species belong-
ing to Mucorales. Indeed, Mucorales represent a large group of fungi
including very diverse species that can be found all over the world.
Among the several hundreds of known species of Mucorales, more
than 20 different species belonging to more than 10 genera can be
responsible for infections in humans.
Although there have been relatively few studies to evaluate the
specific characteristics of each species it is clear that they are very
diverse in terms of genetics and biology, geographical distribution
and epidemiology, antifungal susceptibility, predisposing factors of
the patients, and clinical presentation of the diseases they are
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causing. This diversity could have a direct impact on the perfor-
mance of diagnostic tools and may have, in the future when more
active drugs are available, an impact on the therapeutic strategies.
Recently, the taxonomy of Mucorales has been largely revised and
molecular studies have shown the great diversity among the genera
and even among species belonging to a given genus. One the practi-
cal consequences of these large genetic variations is that a single
DNA target (ITS region) can be easily used for a precise molecular
identification of almost all the pathogenic species.
Although Mucorales seems to be worldwide distributed, the fre-
quency of the species is related to the geographical area. For exam-
ple, species belonging to Saksenaea or Apophysomyces are more often
recovered in tropical countries and Lichtheimia species seems more
frequent in Europe than in North America.
They are also difference between species for their antifungal sus-
ceptibility. Some species such as Cunninghamella spp. are less suscepti-
ble to amphotericin B than others and variable susceptibilities to
posaconazole have also been reported among Mucorales. The clinical
impact of these differences are nevertheless currently largely
unknown.
The underlying conditions of the patients with Mucormycosis and
the clinical presentation of the disease is also dependent on the spe-
cies. Some species such as Saksenaea and Apophysomyces are mainly
responsible of post-traumatic cutaneaous/subcutaneous infections in
immunocompetent patients. In contrast, Rhizopus species are more
often responsible for rhino-cerebral infections in diabetic patients.
Overall, the group of human pathogenic Mucorales, which is often
considered as a homogeneous group of fungi, is in fact constituted by
a series of very diverse species.
M10b
Are all potential human pathogenic Mucorales identical?
D. P. Kontoyiannis
The University of Texas MD Anderson Cancer Center, Houston,
TX, USA
Species of Rhizopus, Mucor and Lichtheimia are the most common
members of the order Mucorales that cause mucormycosis, account-
ing for 70–80% of all cases. In contrast, species of Cunninghamella,
Apophysomyces, Saksenaea, Rhizomucor, Cokeromyces, Actinomucor and
Syncephalastrum individually responsible for <1–5% of reported cases
of mucormycosis. Clinical presentation, host predilection, and out-
comes seem to vary as a function of the degree and type of immune
dysfunction, geoclimatic locale and species of Mucorales. Epidemiol-
ogy, clinical presentations and outcome of unusual Mucorales are
less well studied and there is particular need for improving clinical
and laboratory diagnosis. New active antifungal drugs and new
treatment strategies to improve the outcome especially for C. berthol-
letiae and R. pusillus are urgently required. Clinical Infectious
Diseasescid.oxfordjournals.org
M11
Rare fungal infections cases
B. Rijnders1 and K. Lagrou2
1Erasmus MC, Rotterdam, the Netherlands and 2University
Hospitals Leuven, Belgium
For the abstracts that will be discussed in this session, please see section
‘poster sessions’, corresponding abstract numbers: P109/P296/P148.
M12a
Indoor fungal exposure and disease: an overview
M. Richardson
University Hospital of South Manchester, Manchester, United
Kingdom
Indoor dampness increases the risk of indoor fungal growth. A com-
plex interaction between occupant behavours and the built environ-
ment are thought to affect indoor fungal concentrations and species
diversity, which are believed to increase the risk of having asthma,
exacerbation of asthma symptoms, or both, and contribute to allergic
bronchopulmonary and chronic pulmonary aspergillosis. Mould
spores and metabolites can be inhaled via the air and cause allergic
and irritating reactions and/or complex symptoms in humans. In
rare cases some mould species, for example, Aspergillus fumigatus,
can cause infections in high risk groups. There is sufficient epidemio-
logical evidence that damp and mouldy buildings increase the risk of
respiratory symptoms, respiratory infections and exacerbations of
asthma symptoms of the occupants. In addition, there is some evi-
dence for increased risk of development of allergic rhinitis and
asthma. Furthermore, there is clinical evidence for rare symptoms
like allergic alveolitis, chronic rhinosinusitis and allergic sinusitis.
Toxicological studies in vivo and in vitro demonstrate that microor-
ganisms can cause short-term irritation (including spores, cell com-
ponents, such as hyphal fragments and metabolites) from damp
buildings. Numerous scientific and clinical studies have demonstrated
that exposure to common environmental moulds in the built envi-
ronment, such as, Aspergillus, Penicillium, Cladosporium, Ulocla-
dium, Acremonium, Epicoccum, Trichoderma, Alternaria, and
Wallemia species might represent a respiratory health risk to atopic
and immunocompromised patients, and patients with other respira-
tory problems, living in homes with increased fungal concentrations.
Many of these surveys do not provide sufficient detail to assess
whether these fungi exacerbated asthma symptoms or potential
health outcomes resulting from increased exposure to known aller-
genic or pathogenic fungal species (ie, fungi only identified to the
genus level, for example: Aspergillus fumigatus instead of Aspergil-
lus/Penicillium) present in higher concentrations at the time of sam-
pling. Development of molecular tools enables us to more reliably
quantify fungal species present indoors.
M12b
Indoor molds and chronic rhinosinusitis: could we improve
detection of fungal spores from the sinuses and prevent
fungal chronic rhinosinusitis (FRS) or invasive infections?
V. S. Arsic Arsenijevic
University of Belgrade, Belgrade, Serbia
Fungi are ubiquitous, found mainly in air, dust, soil, plants and decay-
ing organic material but degree of fungal exposure appears to vary
based on environmental conditions. Moisture in buildings becomes a
critical factor for fungal proliferation and dissemination. Nutrients and
moisture increase fungal adherence to dust particles which may be
inhaled and deposited on the sinus mucosa, whose warm, moist envi-
ronment is ideal for further fungal proliferation. The literature shows
increasing appearance of noninvasive fungal inflammations of upper
respiratory tract in immunocompetent patients (allergic and nonaller-
gic) and invasive fungal infections (IFI) in immunocompromised
patients as fungi could persist in sinuses as ‘hidden-killers’.
Chronic rhinosinusitis (CRS) is inflammatory disease of the nasal
and paranasal sinus mucosa with symptoms persisting longer than
3 months. CRS is one of the most common chronic diseases world-
wide (prevalence in USA 14.1%). Several recent studies revealed the
role of fungi in the pathogenesis of CRS but it is still controversial. It
seems that different environmental/geographical conditions, fungal
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species, patient’s predisposition and risk factors are crucial in devel-
oping fungal CRS (FRS).
There is a great interest related to indoor fungi and upper respira-
tory tract diseases but the main problem is ‘evidence based diagno-
sis’confirmed by mycology examination. Traditional methods for
fungal detection, such as nasal swab, show low sensitivity and speci-
ficity, while the sampling of sinus mucine and tissue is complex and
invasive. It results in the needs for developing and standardizing pro-
tocols for representative samples selection and proceeding in order to
improve detection of fungi from the sinuses.
We focused on: (i) CRS patients and developing of personalized
approach for prediction of FRS and (ii) standardization of diagnostic
protocols which could improve detection of fungi from the sinuses.
During 2014th we done clinical and mycological examinations on
157 CRS patients: 43 with nasal polyps (NP) underwent surgery and
112 without surgery. According to obtained data 10 ‘major’ CRS crite-
ria were selected as key FRS predictors (‘FRSindex’). We developed two
types of sampling procedures that shown high sensitivity and speci-
ficity for fungal detection from the sinuses: (i) NP tissue obtained by
surgery and proceeded to single cell suspension (SCS) and (ii) sinus
mucine obtained after nasal cavum pretreatment in aim to remove
nasal microbiome followed by induction of sino-nasal secretion (ISNS)
and concomitant sampling by lavage and aspiration (ISNScomb
method). SCS and ISNScomb methods significantly enhance detection of
relevant fungi from the sinuses, compared to nasal swab methods or
pathohistology. The highest positive fungal findings we found out in
group of patients with: recalcitrant NP (42%), CRS without surgery
(25%) and NP (23%). ISNScomb method showed the highest sensitivity
and specificity (89%, 96%; respectively) and PPV and NPV (94%,
93%; respectively), according to developed FRSindex. Based on these
data we showed prevalence of CRS in Serbia 13.8% and prevalence of
FRS 2.8%. Out of 43 patients with NP 10 had positive fungal finding:
A. flavus, A. niger and Alternaria alternata. Out of 112 patients without
surgery 28 had positive fungal finding: Aspergillus (A. fumigatus,
A. flavus, A. niger), Penicillium, Cladosporium, Rhizopus, Alternaria and
Fusarium. In home air samples from 71 we revealed 224 indoor
molds: Aspergillus (A. flavus, A. nidulans, A. versicolor, A. glaucus, A. fu-
migatus, A. niger, A. terreus), Penicillium, Curvularia, Fusarium, Rhizo-
pus, Alternaria, Chrysosporium and Ulocladium. The most abound
indoor molds were A. niger (62/224) and Penicillium (29/224).
In conclusion We could improve detection of fungi from the sinuses
by developing and standardizing of reproducible, sensitive and cost-ef-
fective methods for FRS diagnosis. It could be strongly important for
immunocompromised patients for preventing life-treating IFI with
timely detection of indoor molds in sinuses, as ‘hidden-killers’.
M13
Sand serves as a reservoir for potentially pathogenic
microorganisms
J. C. Branda˜o1 and N. Gunde-Cimerman2
1National Institute of Health Dr. Ricardo Jorge, Lisboa, Portugal
and 2Biotechnical Faculty, University of Ljubljana, Ljubljana,
Slovenia
Recent studies suggest that sand can serve as a vehicle for exposure
of humans to potential pathogenic microorganisms at beach sites,
sandboxes and recreational areas. Recreational water quality, world-
wide, focuses on monitoring bacterial indicators of possible faecal
contamination by pathogens that cause Gastro-intestinal illness. The
most recent bathing water directive in Europe hints on recreational
water surrounding areas as a possible contamination source in itself.
Yet, it leaves behind a clear message that sand is a relevant source
of microorganisms, despite WHO’s recommendation of sand monitor-
ing in 2003; especially in regions where beach users stay mainly on
the sand due to low temperatures of the water. This recommendation
has been backed up recently by an epidemiological study conducted
by Heaney et al. (2012) and the information collected during a
5 year beach sand monitoring program of the whole of the coast of
Portugal (Sabino et al. 2011).
Given the diversity of microbes found in sand, studies are urgently
needed to identify the most significant aetiologic agent of disease that
may be conveyed through sand, and to relate microbial measure-
ments to human health risk. Currently monitoring in sandboxes is
limited to measurements of Toxocara eggs, although other microbes
have been documented. A newly emerging group of fungi of concern
include the black yeast-like fungi and in non-coastal settings, Crypto-
coccus gattii has been gaining significance already given to endemic
and fungi resistant to antimicrobials, especially in Children and
immune-impared individuals. Sampling for microorganisms in sand
should therefore be considered for inclusion in regulatory programs
aimed at protecting recreational users from infectious disease (Solo-
Gabriel et al. in press).
Overall, we recommend environmental studies to support the link
between fungi exposure in sand and human health impacts, and also
to review existing sand analysis to make sure that other potential
pathogens are cover.
References Heaney CD, Sams E, Dufour AP et al (2012) Feacal indi-
cators in sand, sand contact, and risk of enteric illness among beach-
goers. Epidemiology, 23, 95–106.
Sabino R, Verissimo C, Cunha M.A, Wergikoski B, Ferreira FC,
Rodrigues R, Parada H, Falcao L, Rosado L, Pinheiro C, Paixao E and
Brandao J (2011) Pathogenic fungi: an unacknowledged risk at
coastal resorts? New insights on microbiological sand quality in Por-
tugal. Marine Pollution Bulletin, 62(7), 1506–1511.
Solo-Gabriele HM, Harwood VJ, Kay D, Fujioka RS, Sadowsky MJ,
Whitman RL, Wither A, Barroso H, Canica M, Carvalho da Fonseca
R, Duarte A, Edge TA, Gargate MJ, Gunde-Cimerman N, Hagen F,
McLellan SL, Nogueira da Silva A, Novak Babic M, Prada S, Rodri-
gues R, Rom~ao D, Sabino R, Samson RA, Segal E, Staley C, Taylor
HD, Verıssimo C, Viegas C and Brand~ao JC. Beach Sand and the
Potential for Infectious Disease Transmission: Observations and Rec-
ommendations. In press. Journal of the Marine Biological Association
of the United Kingdom - Special Issue on Oceans and Human Health.
M14
Oral candidosis and cancer, a relation?
R. Richardson1 and M. T. Nieminen2
1University of Manchester and University Hospital of South
Manchester, Manchester, United Kingdom and 2University of
Helsinki, Helsinki, Finland
In this session we will summarise and discuss the current knowledge
on the role of Candida yeasts in the development of cancer. In addi-
tion, cases where a link between chronic candidosis and malignant
transformation can be hypothesised will be presented.
Cancer is one of the leading causes of death worldwide. There is a
strong link between chronic inflammation and many types of can-
cers, and suppression or dysregulation of the immune system
increases the risk for their develoopment. Oral candidosis is common
in patients with malignancies whereby the presence of Candida has
logically been assumed to reflect the opportunistic nature of the yeast
rather than its role in the development of a malignant lesion. Our
group has focused its research on the biofilm-associated chronic oral-
oesophageal candidosis, which has been shown to be potentially car-
cinogenic in vivo. The most important etiological factors of upper
digestive tract cancers are alcohol consumption and smoking. Certain
dietary and genetic factors as well as poor oral hygiene can also con-
tribute to the increased risk. All these factors lead to increased expo-
sure of the upper digestive tract mucosa to mutagenic acetaldehyde
(ACH). ACH is the first metabolite of ethanol metabolism and fermen-
tation. It binds to DNA and forms DNA adducts, causes point muta-
tions, DNA crosslinking and interferes with the synthesis and repair
of DNA, and is classified as a Group 1 carcinogen by WHO. We have
shown that most Candida spp. can produce mutagenic levels of ACH,
especially when grown in hypoxic/anaerobic conditions and as
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biofilms. Therefore, in addition to inducing pro-inflammatory path-
ways Candida has the potential to induce carcinogenesis also by pro-
ducing mutagenic by-products. These findings provide an
explanation for the carcinogenicity of chronic oral-oesophageal can-
didosis, and indicate that Candida can be the cause for the develop-
ment of a cancerous lesion in addition to being a secondary
coloniser.
M15
Candida pneumonia in ICU?
D. Bergmans1 and M. Tumbarello2
1Maastricht University Medical Centre, Maastricht, the
Netherlands and 2UCSC, Roma, Italy
Candida species are frequently found in tracheal aspirate specimens
even in healthy patients. After 48 hours of intubation and ventila-
tion more than 20% of patients are colonized with Candida species at
the tracheobronchial site. This proportion increases with the dura-
tion of ventilation. Studies analyzing bronchoalveolar lavage fluid
(BALF) cultures from critically ill patients found up to 8% positivity
for Candida, the majority of which were thought to be colonization or
inconclusive and less than 5% classified as ventilator-associated
pneumonia (VAP) by the treating physician. Although antifungal
treatment is scarcely initiated, none of these patients appear to
develop systemic candidiasis. Treatment of all patients with BALF
analysis positive for Candida would result in excessive use of antifun-
gal agents with risk of rapid development of drug resistance. Sheer
presence of Candida in the BALF obviously does not prove a patho-
genetic role of this microorganism in the development of pneumonia.
Moreover, the radiological morphology of Candida lesions is diverse.
Bronchopneumonia, abscesses, granulomas, intracavitary membra-
nous exudates have all been described on X-ray and on high resolu-
tion chest tomography. The real incidence of Candida pneumonia is
thus notoriously difficult to determine. The most reliable method
would be lung histology and proof of an association between Candida
lung invasion and local inflammation. The patients clinical condition,
high oxygen dependency and thrombocytopenia, commonly present,
often exclude the possibility of pulmonary biopsies. Therefore, most
reports of Candida pneumonia are based on isolation of Candida from
sputum aspirates or BALF in the absence of other causative patho-
gens. Studies in critically ill, ventilated and non-neutropenic patients
with quantitative cultures from tracheal aspirate and BALF failed to
discriminate presence from absence of Candida pneumonia established
by autopsy findings. It was even suggested that there is no evidence
for the existence for such clinical entity at all. Taking into account
the high number of patients colonized with Candida species in the tra-
cheal tract it seems a convincing conclusion that colonization alone
does not lead to pulmonary infection. Furthermore, Candida species
are at most a very rare cause of pneumonia. But to rule out the exis-
tence of Candida pneumonia as a clinical entity at all may be prema-
ture. An interesting question would be whether those Candida species
colonizing the tracheobronchial tree are merely innocent bystanders?
It has been shown that mechanically ventilated patients colonized
with Candida species were more at risk to develop Pseudomonas aerugi-
nosa VAP and in those patients who received antifungal treatment
the incidence of VAP was reduced. Furthermore, colonization with
Candida species is an independent risk factor for increased morbidity
and mortality in ICU patients. But whether colonization with Candida
has a causative role or is merely a marker for poor outcome is
unclear.
An increasing number of immunocompromized patients due to
immunosuppressive therapy, malignancies and infections are treated
in ICU who are at risk to develop Candida pneumonia. Moreover,
there are genetic associations that determine the susceptibility for
Candida infections. Therefore, Candida as the causative microorganism
of pneumonia in ICU patients should be considered in differential
diagnosis. Candida pneumonia is a rare entity. But there is evidence
that the condition can occur under certain clinical circumstances: (i)
immunosuppression by cancer, sepsis, drugs, malnutrition, (ii) risk
factors for increased Candida load as diabetes mellitus, nicotine and
alcohol abuse, aspiration of gastric fluids, diverticulum of the esopha-
gus, (iii) broad spectrum antibiotic treatment. Quantitative cultures
of BALF appears the diagnostic approach of choice in absence of
histology.
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